Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Makoto Azumi"'
Autor:
Esteban Celis, Yasuaki Harabuchi, Masatoshi Tateno, Makoto Azumi, Naoko Aoki, Shoji Kimura, Keisuke Sato, Miki Takahara, Toshihiro Nagato, Hiroya Kobayashi
EBV-encoded latent membrane protein 1 (LMP1) has oncogenic potential and is expressed in many EBV-associated malignancies. Although LMP1 is regarded as a potential tumor-associated antigen for immunotherapy and several LMP1-specific MHC class I–res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0db28e4ebfa3bb8d8c7d0dfeb9866bef
https://doi.org/10.1158/0008-5472.c.6497141.v1
https://doi.org/10.1158/0008-5472.c.6497141.v1
Autor:
Esteban Celis, Masatoshi Tateno, Hidehiro Kakizaki, Makoto Azumi, Hajime Iizuka, Masamoto Murakami, Shoji Kimura, Naoko Aoki, Keisuke Sato, Toshihiro Nagato, Hiroya Kobayashi
The six-transmembrane epithelial antigen of prostate (STEAP) protein is an attractive candidate for T cell–based immunotherapy because it is overexpressed in prostate cancer and various other tumor types. Several peptide epitopes capable of stimula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::358120fd89fdc2fdbb14af5f0cf23569
https://doi.org/10.1158/0008-5472.c.6495476
https://doi.org/10.1158/0008-5472.c.6495476
Autor:
Esteban Celis, Masatoshi Tateno, Hidehiro Kakizaki, Makoto Azumi, Hajime Iizuka, Masamoto Murakami, Shoji Kimura, Naoko Aoki, Keisuke Sato, Toshihiro Nagato, Hiroya Kobayashi
Supplementary Figures S1-S2 from Recognition of Prostate and Melanoma Tumor Cells by Six-Transmembrane Epithelial Antigen of Prostate–Specific Helper T Lymphocytes in a Human Leukocyte Antigen Class II–Restricted Manner
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4109f2a10f29965a811c232ecbffde36
https://doi.org/10.1158/0008-5472.22367240.v1
https://doi.org/10.1158/0008-5472.22367240.v1
Autor:
Esteban Celis, Yasuaki Harabuchi, Masatoshi Tateno, Makoto Azumi, Naoko Aoki, Shoji Kimura, Keisuke Sato, Miki Takahara, Toshihiro Nagato, Hiroya Kobayashi
Supplementary Figure 1 from Induction of EBV–Latent Membrane Protein 1–Specific MHC Class II–Restricted T-Cell Responses against Natural Killer Lymphoma Cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::689c9a96313321fe43528b40765539dc
https://doi.org/10.1158/0008-5472.22373594
https://doi.org/10.1158/0008-5472.22373594
Autor:
Esteban Celis, Yasuaki Harabuchi, Masatoshi Tateno, Makoto Azumi, Naoko Aoki, Shoji Kimura, Keisuke Sato, Miki Takahara, Toshihiro Nagato, Hiroya Kobayashi
Supplementary Figure 2 from Induction of EBV–Latent Membrane Protein 1–Specific MHC Class II–Restricted T-Cell Responses against Natural Killer Lymphoma Cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d8f0669b5c73ed50e77efbabfc5e9ef
https://doi.org/10.1158/0008-5472.22373591.v1
https://doi.org/10.1158/0008-5472.22373591.v1
Autor:
Esteban Celis, Yasuaki Harabuchi, Masatoshi Tateno, Makoto Azumi, Naoko Aoki, Shoji Kimura, Keisuke Sato, Miki Takahara, Toshihiro Nagato, Hiroya Kobayashi
Supplementary Figure Legends 1-2, Methods from Induction of EBV–Latent Membrane Protein 1–Specific MHC Class II–Restricted T-Cell Responses against Natural Killer Lymphoma Cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f5637ecbc0d5cc4454e2b37c2cdd2bb
https://doi.org/10.1158/0008-5472.22373588.v1
https://doi.org/10.1158/0008-5472.22373588.v1
Publikováno v:
British journal of clinical pharmacologyREFERENCES. 87(4)
It remains unclear whether therapeutic drug monitoring (TDM) of pazopanib improves treatment outcomes in routine clinical practice. We did a prospective cohort study to evaluate the benefits of TDM for pazopanib therapy in real-world practice. Among
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::787f7bcd365f03a255f323fa0b82b409
https://pubmed.ncbi.nlm.nih.gov/33010046
https://pubmed.ncbi.nlm.nih.gov/33010046
Autor:
Seiji Matsumoto, Masahide Fukudo, Gaku Tamaki, Makoto Azumi, Hidehiro Kakizaki, Yoshikazu Tasaki
Publikováno v:
Investigational new drugs. 39(2)
Purpose Axitinib is an orally active multikinase inhibitor currently used to treat patients with metastatic renal cell carcinoma (RCC). This study examined the pharmacokinetics of axitinib and the relationship between peak drug concentration (Cmax) a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56d45c3b645de10cfd9c7c9d8826f52a
https://pubmed.ncbi.nlm.nih.gov/33098047
https://pubmed.ncbi.nlm.nih.gov/33098047
Autor:
Miyu Tsuchida, Gaku Tamaki, Naoki Wada, Masafumi Kita, Hiroko Banjo, Junichi Hori, Hidehiro Kakizaki, Makoto Azumi, Masaki Watanabe
Publikováno v:
International journal of urology : official journal of the Japanese Urological Association. 25(5)
Objectives To examine the long-term persistence rate with mirabegron in a real-world clinical setting. Methods We retrospectively collected the data of patients who were prescribed mirabegron. We investigated the persistence rate and the reason for t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32ed778d103fbea1d3842fc1f3351a0e
https://pubmed.ncbi.nlm.nih.gov/29651798
https://pubmed.ncbi.nlm.nih.gov/29651798
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 44(9)
To evaluate the diagnostic efficacy of percutaneous renal tumor biopsy.We retrospectively investigated 23 patients who underwent percutaneous renal tumor biopsy since 2008 at Department of Renal and Urologic Surgery, Asahikawa Medical University Hosp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d5fada58635f21251e8741cd87cfcddc
https://pubmed.ncbi.nlm.nih.gov/28912407
https://pubmed.ncbi.nlm.nih.gov/28912407